📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. (2023)

First Author: Mascarenhas J

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1200/jco.22.01972

PubMed Identifier: 36881782

Publication URI: http://europepmc.org/abstract/MED/36881782

Type: Journal Article/Review

Volume: 41

Parent Publication: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Issue: 32

ISSN: 0732-183X